Comparison study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus - DURATION-NEO-2

Exclusion Criteria

• - History of pancreatitis or triglycerides >=500 mg/dL
• - Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either
• - History of renal transplantation, or is currently receiving renal dialysis, or has an estimated creatinine clearance <50 mL/min
• - Active cardiovascular disease
• - Presence or history of severe congestive heart failure
• - Central nervous system disease, including epilepsy
• - Liver disease
• - History of severe gastrointestinal diseases
• - Clinically significant malignant disease
• - Repeated severe hypoglycemia within the last 6 months
• - Any exposure to exenatide (BYETTA® or BYDUREON™) or any GLP-1 analog
• - Any DPP-4 inhibitor within 3 months prior screening